Thomas Klein

7PUBLICATIONS

19CO-AUTHORS

PharmacogenomicsMolecular targetsCharacterisation of biological macromoleculesBiomolecular modelling and designClinical pharmacology and therapeutics

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (7)

Sort by Publication Date:

|Oct 01, 2026

Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.

|Oct 15, 2025

Pre-stroke weight loss by glucagon-like peptide 1 receptor and neuropeptide Y receptor Y2 activation improves post-stroke functional recovery in male diabetic mouse models.

Ellen Vercalsteren, Dimitra Karampatsi, Maria Neicu

|Apr 21, 2021

Urinary dipeptidyl peptidase-4 protein is increased by linagliptin and is a potential predictive marker of urine albumin-to-creatinine ratio reduction in patients with type 2 diabetes.

Thomas Klein, Harald Tammen, Michael Mark

|Dec 21, 2020

Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease.

Herbert Nar, Gisela Schnapp, Oliver Hucke

|Oct 08, 2020

A Single Second Shell Amino Acid Determines Affinity and Kinetics of Linagliptin Binding to Type 4 Dipeptidyl Peptidase and Fibroblast Activation Protein.

Gisela Schnapp, Yvette Hoevels, Remko A Bakker

|Feb 17, 2015

Prostacyclin synthase: upregulation during renal development and in glomerular disease as well as its constitutive expression in cultured human mesangial cells.

Thomas Klein, Günther Klaus, Martin Kömhoff

Pageof 2

Frequent Collaborators

Gisela Schnapp

Herbert Nar

Martin Kömhoff

Yvette Hoevels

Remko A Bakker

Patrick Schreiner

Oliver Hucke

Timothy C Hardman

Ellen Vercalsteren

Dimitra Karampatsi

Frequent Collaborators

Gisela Schnapp

Herbert Nar

Martin Kömhoff

Yvette Hoevels